in patients with chronic rhinosinusitis with nasal polyps (CRSwNP). The therapy met the co-primary endpoint of the WAYPOINT ...

(IN BRIEF) A Phase III trial of Tezspire (tezepelumab) by AstraZeneca and Amgen has shown significant benefits for patients ...

November 08, 2024--(BUSINESS WIRE)--Positive high-level results from the Phase III WAYPOINT trial in patients with chronic rhinosinusitis with nasal polyps (CRSwNP ... significant and clinically ...

A deviated septum occurs when you have two different-sized nasal passageways which can cause one-sided congestion.

often resulting from chronic inflammation. While these benign growths themselves are not harmful, they can lead to ...

Amgen (NASDAQ:AMGN) and AstraZeneca (NASDAQ:AZN) announced Friday that their FDA-approved asthma therapy Tezspire reached ...

Results from the Phase III WAYPOINT trial in patients with chronic rhinosinusitis with nasal polyps showed that AstraZeneca (AZN) and ...

Am­gen and As­traZeneca said on Fri­day that their asth­ma drug Tezspire re­duced nasal con­ges­tion and the size of nasal ...

Amgen (AMGN) and AstraZeneca (AZN) announced top-line results from the Phase 3 WAYPOINT trial in patients with chronic rhinosinusitis with ...

(Alliance News) - AstraZeneca PLC on Friday said it received positive results from a trial of Tezspire as a treatment for chronic rhinosinusitis with nasal polyps.

HYDERABAD: While the monsoon season saw an ambush of vector-borne diseases such as dengue and chikungunya in the state, ...

compared to a placebo in adults with severe chronic rhinosinusitis with nasal polyps, showed a "statistically significant and ...